# Xilio Therapeutics, Inc.: financial statements, quarterly

XLO · Nasdaq · CIK 1840233 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xlo.md) · [Financials](/companies/xlo/financials.md) · [Filings](/companies/xlo/filings.md) · [Insiders](/companies/xlo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xlo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [2.4](/filings/0001558370-25-011477.md) | [2.3](/filings/0001193125-25-278837.md) | [1.7 d](/filings/0001193125-26-118550.md) | [2.9](/filings/0001193125-26-218200.md) | [8.1](/filings/0001193125-26-345759.md) | [19.1](/filings/0001193125-25-278837.md) | [13.7 d](/filings/0001193125-26-118550.md) | [12.6](/filings/0001193125-26-218200.md) | [18.7](/filings/0001193125-26-345759.md) |
| Research and development | $m | [11.1](/filings/0001558370-24-014775.md) | [11.7 d](/filings/0001558370-25-002640.md) | [10.4](/filings/0001558370-25-006996.md) | [11.2](/filings/0001558370-25-011477.md) | [10.8](/filings/0001193125-25-278837.md) | [8.8 d](/filings/0001193125-26-118550.md) | [8.3](/filings/0001193125-26-218200.md) | [15.3](/filings/0001193125-26-345759.md) | [14.3](/filings/0001193125-25-278837.md) | [18.1 d](/filings/0001193125-26-118550.md) | [19.8](/filings/0001193125-26-218200.md) | [14.6](/filings/0001193125-26-345759.md) |
| Operating income | $m | [(17.4)](/filings/0001558370-24-014775.md) | [(18.1) d](/filings/0001558370-25-002640.md) | [(17.5)](/filings/0001558370-25-006996.md) | [(14.7)](/filings/0001558370-25-011477.md) | [(14.8)](/filings/0001193125-25-278837.md) | [(13.6) d](/filings/0001193125-26-118550.md) | [(13.9)](/filings/0001193125-26-218200.md) | [(14.4)](/filings/0001193125-26-345759.md) | [(1.9)](/filings/0001193125-25-278837.md) | [(11.8) d](/filings/0001193125-26-118550.md) | [(14.1)](/filings/0001193125-26-218200.md) | [(3.5)](/filings/0001193125-26-345759.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(16.7)](/filings/0001558370-24-014775.md) | [(17.7) d](/filings/0001558370-25-002640.md) | [(17.2)](/filings/0001558370-25-006996.md) | [(13.9)](/filings/0001558370-25-011477.md) | [(14.0)](/filings/0001193125-25-278837.md) | [(13.1) d](/filings/0001193125-26-118550.md) | [(13.3)](/filings/0001193125-26-218200.md) | [(15.8)](/filings/0001193125-26-345759.md) | [(16.3)](/filings/0001193125-25-278837.md) | [10.4 d](/filings/0001193125-26-118550.md) | [(9.5)](/filings/0001193125-26-218200.md) | [(6.4)](/filings/0001193125-26-345759.md) |
| Diluted EPS | $ per share | [(0.61)](/filings/0001558370-24-014775.md) | not reported | [(0.62)](/filings/0001558370-25-006996.md) | [(0.24)](/filings/0001558370-25-011477.md) | [(0.22)](/filings/0001193125-25-278837.md) | not reported | [(2.49)](/filings/0001193125-26-218200.md) | [(2.30)](/filings/0001193125-26-345759.md) | [(0.11)](/filings/0001193125-25-278837.md) | not reported | [(0.58)](/filings/0001193125-26-218200.md) | [(0.33)](/filings/0001193125-26-345759.md) |
| Basic EPS | $ per share | [(0.61)](/filings/0001558370-24-014775.md) | not reported | [(0.62)](/filings/0001558370-25-006996.md) | [(0.24)](/filings/0001558370-25-011477.md) | [(0.22)](/filings/0001193125-25-278837.md) | not reported | [(2.49)](/filings/0001193125-26-218200.md) | [(2.30)](/filings/0001193125-26-345759.md) | [(0.11)](/filings/0001193125-25-278837.md) | not reported | [(0.58)](/filings/0001193125-26-218200.md) | [(0.33)](/filings/0001193125-26-345759.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [59.8](/filings/0001558370-24-014775.md) | [44.7](/filings/0001558370-25-002640.md) | [34.0](/filings/0001558370-25-006996.md) | [74.9](/filings/0001558370-25-011477.md) | [61.3](/filings/0001193125-25-278837.md) | [55.3](/filings/0001193125-26-118550.md) | [89.1](/filings/0001193125-26-218200.md) | [122](/filings/0001193125-26-345759.md) | [104](/filings/0001193125-25-278837.md) | [138](/filings/0001193125-26-345759.md) | [150](/filings/0001193125-26-218200.md) | [136](/filings/0001193125-26-345759.md) |
| Current assets | $m | [64.5](/filings/0001558370-23-018587.md) | [48.1](/filings/0001558370-25-002640.md) | [69.2](/filings/0001558370-24-008068.md) | [78.0](/filings/0001558370-24-011471.md) | [63.3](/filings/0001558370-24-014775.md) | [60.2](/filings/0001193125-26-118550.md) | [93.2](/filings/0001558370-25-006996.md) | [124](/filings/0001558370-25-011477.md) | [124](/filings/0001193125-25-278837.md) | [145](/filings/0001193125-26-345759.md) | [154](/filings/0001193125-26-218200.md) | [145](/filings/0001193125-26-345759.md) |
| Total assets | $m | [77.8](/filings/0001558370-23-018587.md) | [60.9](/filings/0001558370-25-002640.md) | [82.6](/filings/0001558370-24-008068.md) | [89.9](/filings/0001558370-24-011471.md) | [74.7](/filings/0001558370-24-014775.md) | [71.1](/filings/0001193125-26-118550.md) | [104](/filings/0001558370-25-006996.md) | [134](/filings/0001558370-25-011477.md) | [134](/filings/0001193125-25-278837.md) | [155](/filings/0001193125-26-345759.md) | [163](/filings/0001193125-26-218200.md) | [154](/filings/0001193125-26-345759.md) |
| Current liabilities | $m | [16.9](/filings/0001558370-23-018587.md) | [16.0](/filings/0001558370-25-002640.md) | [31.6](/filings/0001558370-24-008068.md) | [38.6](/filings/0001558370-24-011471.md) | [38.0](/filings/0001558370-24-014775.md) | [27.3](/filings/0001193125-26-118550.md) | [47.6](/filings/0001558370-25-006996.md) | [53.3](/filings/0001558370-25-011477.md) | [56.4](/filings/0001193125-25-278837.md) | [56.3](/filings/0001193125-26-345759.md) | [43.0](/filings/0001193125-26-218200.md) | [34.2](/filings/0001193125-26-345759.md) |
| Total liabilities | $m | [25.3](/filings/0001558370-23-018587.md) | [24.1](/filings/0001558370-25-002640.md) | [56.8](/filings/0001558370-24-008068.md) | [56.5](/filings/0001558370-24-011471.md) | [53.7](/filings/0001558370-24-014775.md) | [53.5](/filings/0001193125-26-118550.md) | [93.0](/filings/0001558370-25-006996.md) | [127](/filings/0001558370-25-011477.md) | [142](/filings/0001193125-25-278837.md) | [119](/filings/0001193125-26-345759.md) | [90.9](/filings/0001193125-26-218200.md) | [82.0](/filings/0001193125-26-345759.md) |
| Shareholders' equity | $m | [52.5](/filings/0001558370-24-014775.md) | [36.8](/filings/0001193125-26-118550.md) | [25.8](/filings/0001558370-25-011477.md) | [33.4](/filings/0001193125-25-278837.md) | [21.0](/filings/0001193125-25-278837.md) | [17.6](/filings/0001193125-26-345759.md) | [10.7](/filings/0001193125-26-345759.md) | [7.1](/filings/0001193125-26-345759.md) | [(8.1)](/filings/0001193125-25-278837.md) | [35.3](/filings/0001193125-26-345759.md) | [72.5](/filings/0001193125-26-345759.md) | [72.3](/filings/0001193125-26-345759.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.4) d](/filings/0001558370-24-014775.md) | [(13.4) d](/filings/0001558370-25-002640.md) | [(10.5)](/filings/0001558370-25-006996.md) | [20.0 d](/filings/0001558370-25-011477.md) | [(13.7) d](/filings/0001193125-25-278837.md) | [(14.2) d](/filings/0001193125-26-118550.md) | [29.0](/filings/0001193125-26-218200.md) | [(14.5) d](/filings/0001193125-26-345759.md) | [(17.5) d](/filings/0001193125-25-278837.md) | [(2.0) d](/filings/0001193125-26-118550.md) | [(22.3)](/filings/0001193125-26-218200.md) | [(18.8) d](/filings/0001193125-26-345759.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-014775.md) | [0.0 d](/filings/0001558370-25-002640.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-278837.md) | [0.0 d](/filings/0001193125-26-118550.md) | [0.0](/filings/0001193125-26-218200.md) | [0.4 d](/filings/0001193125-26-345759.md) | [0.0 d](/filings/0001193125-25-278837.md) | [0.1 d](/filings/0001193125-26-118550.md) | [0.6](/filings/0001193125-26-218200.md) | [0.0 d](/filings/0001193125-26-345759.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Shares outstanding: 5,782,511 at 2026-03-18, from the cover of the [10-K filed 2026-03-23](/filings/0001193125-26-118550.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.